Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares
Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP, and David Kroin, has reported a 9.99% beneficial ownership stake in Altimmune (ALT). This stake, amounting to 19,417,221 shares, includes common stock, pre-funded warrants, and warrants, all subject to a 9.99% maximum exercise limitation. The disclosure was made via a Schedule 13G filing as of April 30, 2026 and is based on 194,366,579 shares outstanding.
How this was made
The 30-second read
Why it matters
While the disclosure indicates institutional interest, it does not necessarily translate into active trading signals or immediate price movements.
Market read
The disclosure is relevant for investors monitoring institutional holdings and potential market sentiment shifts in ALT.
What to watch
Broader market conditions, company fundamentals, and upcoming catalysts are critical to assess before making trading decisions.
Background
Institutional investors are required to disclose holdings exceeding 5% in US-listed companies, providing transparency about significant passive interests.
Ticker impact
The disclosed 9.99% passive stake in Altimmune (ALT) indicates significant institutional interest, which can influence market perception and stock price movements.
Potential for moderate upward price movement if market interprets increased institutional interest as positive; however, the passive nature limits immediate impact.
The passive stake indicates interest but lacks active trading signals; market reaction depends on broader context and investor perception.
Market effects
Possible increased investor focus on biotech and life sciences sectors due to institutional activity in ALT.
Limited regional impact; primarily relevant to US markets where ALT is listed.
Minimal; the news pertains to a specific US-listed company with no immediate global implications.
Counterpoint
Passive stake may not lead to significant price change; market may have already priced in institutional interest.
Key entities
- Institutional InvestorDeep Track Capital
A hedge fund or investment firm reporting a 9.99% stake in ALT.
- CompanyAltimmune (ALT)
A biotech company in the life sciences sector.

